<DOC>
	<DOCNO>NCT00439634</DOCNO>
	<brief_summary>AVE1625 new potent selective cannabinoid 1 ( CB1 ) antagonist clinical development treatment cognitive impairment patient diagnose schizophrenia . The main objective study evaluate efficacy cognitive impairment 3 dos AVE1625 use new cognitive battery call Measurement Treatment Research Improve Cognition Schizophrenia ( MATRICS ) schizophrenic patient . The secondary objective measure efficacy AVE1625 functional capacity patient use specific scale call University California San Diego Performance-based Skills Assessment 2 ( UPSA2 ) ass safety compound .</brief_summary>
	<brief_title>Efficacy Safety AVE1625 Co-treatment With Antipsychotic Therapy Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Outpatients diagnosis schizophrenia ( diagnose â‰¤ 35 year age ) . Current treatment consist exclusively olanzapine , risperidone/paliperidone , quetiapine aripiprazole monotherapy least 2 month . Inpatient hospitalization within past 3 month . Residence current address &lt; 3 month due instability disease . Presence depressive symptom . Past history clinically significant violent behavior . Substance dependence abuse . Pregnant breastfeed woman woman protect effective contraceptive method birth control . The investigator evaluate whether reason patient may participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>psychometrics</keyword>
	<keyword>schizophrenia</keyword>
</DOC>